Skip to content
Baret News – Lifestyle
Author:
Neuraxpharm
European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease
September 25, 2026